Two of these DUBs, PSMD7 and PSDM14, are component of the proteasome, and might therefore be of direct relevance to therapy, including patient stratification, in light of the fact that the proteasome inhibitor bortezomib has already been approved for the treatment of multiple myeloma and mantle cell lymphoma [43], and that additional clinical trials for the treatment of solid tumors and other hematological malignancies are in progress [44]. This evidence concerns the gene PSMD7 and hematologic disorder.